Pharsight

1. List of Cosela drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9957276	G1 THERAP	CDK inhibitors	Oct, 2031 (8 years from now)
US8598197	G1 THERAP	CDK inhibitors	Oct, 2031 (8 years from now)
US10189849	G1 THERAP	CDK inhibitors	Oct, 2031 (8 years from now)
US8598186	G1 THERAP	CDK inhibitors	Oct, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850	G1 THERAP	CDK inhibitors	Oct, 2031 (8 years from now)
US10927120	G1 THERAP	CDK inhibitors	Oct, 2031 (8 years from now)
US9487530	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (10 years from now)
US10085992	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (10 years from now)
US10966984	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (10 years from now)
US11040042	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (10 years from now)
US11529352	G1 THERAP	Preservation of immune response during chemotherapy regimens	Jul, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: 2025-02-12

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung can...

Dosage: POWDER;INTRAVENOUS